People in the study had mild to severe plaque psoriasis, and the plaques covered 3% to 20% of their body surface area (BSA). Vtama cream or the placebo cream was applied once a day to plaque lesions.

Zoryve is also available in a 0.3% cream formulation for the treatment of plaque psoriasis, including intertriginous areas, in adult and pediatric patients 6 years of age and older. References: ...

Source Reference: Gooderham MJ, et al "Roflumilast foam, 0.3%, for psoriasis of the scalp and body: The ARRECTOR phase 3 randomized clinical trial" JAMA Dermatol 2025; DOI: 10.1001/jamadermatol ...

A total of 432 patients (56.3% women) aged 12 and older with psoriasis on the scalp and body were randomly assigned to two groups, one of which used roflumilast foam 0.3% once a day for eight ...

Arcutis Biotherapeutics has received FDA approval for ZORYVE (roflumilast) topical foam 0.3%, which is now available for treating plaque psoriasis on the scalp and body in patients aged 12 and older.

Roflumilast foam is a once-daily steroid-free topical which can be applied to the scalp and body. “Treating plaque psoriasis in areas like the scalp, face, and groin is especially challenging.

Since revealing her plaque psoriasis diagnosis in 2015, La La Anthony has become a powerful voice for those living with the chronic skin condition. Plaque psoriasis-often mistaken for dry skin or ...

TUESDAY, May 27, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has approved Zoryve (roflumilast) topical foam 0.3 percent for the treatment of plaque psoriasis of the scalp ...

Livzon Mabpharm Inc.’s anti-IL-17A/F monoclonal antibody, LZM-012, met the primary endpoint in a phase III trial in moderate to severe plaque psoriasis. Conducted at Fudan University’s Huashan ...

84% of adolescents with moderate-to-severe plaque psoriasis treated with investigational icotrokinra achieved clear or almost clear skin (IGA 0/1) at Week 16 ICONIC-LEAD is the first ever Phase 3 ...